Wockhardt dips after the US FDA asks to recall drugs

Due to deviations in current good manufacturing practice norms stated by US Fod and Drug Administration (FDA)

Shares of drug maker Wockhardt are trading lower by 3% to Rs 1,329 on the Bombay Stock Exchange (BSE) after the company recalled over 200 bottles of Captopril tablets, used in treatment of blood pressure, and Clarithromycin antibiotic tablets manufactured in the US because of deviations in current good manufacturing practice norms stated by US Food and Drug Administration (FDA). CLICK FOR FULL REPORT

According to the US FDA, 166 bottles of captopril tablets of 50 mg strength has been recalled along with 50 bottles of clarithromycin tablets of 500 mg strength.

Blenheim Pharmacal, the packaging company, is the recalling firm while the drugs were distributed by Wockhardt USA LLC, the US subsidiary of the Mumbai-based pharma company.

The stock opened at Rs 1,366, touched a low of Rs 1,322 on the BSE. A total of 55,632 shares changed hands on the BSE.